A deep dive on Big Pharma and Ozempic

In this episode Samo Burja and Erik Torenberg discuss Astra Zeneca and the dysfunction of Big Pharma, its lack of innovation and potential ramifications despite its enormous economic power, incentives behind scientific breakthroughs and the potential for improvement, truth vs profit and changing the FDA's approval processes. Head to brave.com/ads and mention “MoZ” when signing up for a 25% discount on your first campaign.

Live Players is part of the Turpentine podcast network. Learn more: www.turpentine.co

We're hiring across the board at Turpentine and for Erik's personal team on other projects he's incubating. He's hiring a Chief of Staff, EA, Head of Special Projects, Investment Associate, and more. For a list of JDs, check out: https://eriktorenberg.com/.

—

Get first-party targeting with Brave's private ad platform: cookieless and future proof ad formats for all your business needs. Performance meets privacy. Head to brave.com/ads and mention “MoZ” when signing up for a 25% discount on your first campaign.

—

LINKS:

Samo’s Bismarck Brief: https://brief.bismarckanalysis.com/

TIMESTAMPS:

(00:00) Introduction to Live Players

(00:28) Discussion on AstraZeneca and Pharmaceutical Innovation

(00:41) The Economic Giant: Pharmaceutical Industry

(01:20) AstraZeneca's Market Capitalization and COVID-19 Vaccines

(02:13) Strategies of Modern Pharmaceutical Giants

(04:08) The Exception to the Industry: Novo Nordisk

(06:31) Disconnects Between Profitability and Innovation

(08:41) Market Failure in Pharmaceutical Industry

(08:50) The Role of Patent System in Pharmaceutical Industry

(15:17) The Need for Scientifically Minded Founders

(30:34) Sponsor: Brave

(31:34) The Role of FDA in Pharmaceutical Industry

(39:16) The Impact of Managerial Approach on Pharmaceutical Industry

(41:59) The Potential Impact of a Beauty Boom

(42:52) Conclusion and Wrap Up